radiolabeled EDG-5506

Radiolabeled EDG-5506 refers to a version of the investigational drug EDG-5506 that has been tagged with a radioactive isotope for use in human mass balance or pharmacokinetic studies. The parent compound, EDG-5506 (also known as sevasemten), is an orally administered small molecule myosin modulator developed by Edgewise Therapeutics. Its mechanism of action involves selectively inhibiting fast skeletal muscle myosin to protect muscle fibers from contraction-induced damage, particularly in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Radiolabeling is typically used for clinical pharmacology studies to track absorption, distribution, metabolism, and excretion but does not alter the underlying mechanism or therapeutic intent of the drug[2][3][7]. The primary indication for both forms is the treatment of DMD and BMD.

Other names

sevasemten